Sangamo Biosciences reported $176.95M in Cash and Equivalent for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acceleron Pharma XLRN:US $ 336.46M 0.26M
Alnylam Pharmaceuticals ALNY:US $ 1093.99M 348.22M
Amgen AMGN:US $ 11969M 5339M
Avrobio Inc AVRO:US $ 201.37M 25.07M
Bayer BAYN:GR € 4316M 927M
Biocryst Pharmaceuticals BCRX:US $ 199.6M 10.72M
Biogen BIIB:US $ 1541.8M 200.2M
Biomarin Pharmaceutical BMRN:US $ 617.14M 24.39M
Bluebird Bio BLUE:US $ 402.46M 48.99M
Gilead Sciences GILD:US $ 6837M 1944M
GlaxoSmithKline GSK:LN 3453M 50M
Intercept Pharmaceuticals ICPT:US $ 428.77M 283.15M
IONIS PHARMACEUT IONS:US $ 1987M 1421.88M
Karyopharm Therapeutics KPTI:US $ 137.4M 3.91M
Novartis NOVN:VX SF 7211M 2094M
Omeros OMER:US $ 7.42M 5.29M
Sangamo Biosciences SGMO:US $ 176.95M 7.08M
Sarepta Therapeutics SRPT:US $ 1599.11M 98.16M
Ultragenyx Pharmaceutical RARE:US $ 197.54M 93.34M
Vertex Pharmaceuticals VRTX:US $ 6275.7M 212.02M
Ziopharm Oncology ZIOP:US $ 91.72M 14.98M